Subsequent Events |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Subsequent Events [Abstract] | |
| Subsequent Events | 12. Subsequent Events
On July 14, 2026, the Company entered into an Amended and Restated Technology Transfer and Exclusive License Agreement with Mabworks Biotech Co., Ltd., which amended and restated the parties’ existing agreement dated January 8, 2025. The amended agreement reflects the advancement of the parties’ collaboration and establishes a framework for additional collaboration on development activities, including clinical trials, as may be mutually agreed by the parties. The milestone payment and royalty provisions of the original agreement remain unchanged. The Company is evaluating the accounting impact of the amended agreement. |